Hellen Veida-Silva

Dr. Hellen Veida-Silva


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
SZStepheny Carneiro de Campos Zani
Stepheny Carneiro de Campos Zani
RWRen Wang
Ren Wang
HVHellen Veida-Silva
Hellen Veida-Silva
RCRobin Clugston
Robin Clugston
JYJessica T. Y. Yue
Jessica T. Y. Yue
Catherine ChanCatherine Chan
Catherine Chan
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is a global health problem. Currently, no pharmacological treatment is approved for NAFLD. Natural health products, including bioactive peptides, are potential candidates to aid in the management of metabolic syndrome-related conditions, including insulin resistance and obesity. In this study, we hypothesized that an egg-white-derived bioactive peptide QAMPFRVTEQE (Peptide 2) would improve systemic and local white adipose tissue insulin sensitivity, thereby preventing high-fat diet-induced exacerbation of pathological features associated with NAFLD, such as lipid droplet size and number, inflammation, and hepatocyte hypertrophy in high-fat diet-fed mice. Similar to rosiglitazone, Peptide 2 supplementation improved systemic insulin resistance during the hyperinsulinemic-euglycemic clamp and enhanced insulin signalling in white adipose tissue, modulating ex vivo lipolysis. In the liver, compared with high-fat diet fed animals, Peptide 2 supplemented animals presented decreased hepatic cholesterol accumulation (p < 0.05) and area of individual hepatic lipid droplet by around 50% (p = 0.09) and reduced hepatic inflammatory infiltration (p < 0.05) whereas rosiglitazone exacerbated steatosis. In conclusion, Peptide 2 supplementation improved insulin sensitivity and decreased hepatic steatosis, unlike the insulin-sensitizing drug rosiglitazone.

15 September 2026 in Diabetes
Verified
Journal Article
Closed access
HVHellen Veida-Silva
Hellen Veida-Silva
MAMaria Amélia Montenegro de Andrade
Maria Amélia Montenegro de Andrade
PZPatrik Saul Barbosa Zarpellon
Patrik Saul Barbosa Zarpellon
MSMichele de Souza Seixas
Michele de Souza Seixas
LDLuiza Mendonça Duarte
Luiza Mendonça Duarte
LELucila Leico Kagohara Elias
Lucila Leico Kagohara Elias
Obesity is marked by chronic low-grade inflammation and impaired thermogenic function of brown adipose tissue (BAT), contributing to decreased energy expenditure. BAT dissipates energy through uncoupling protein 1 (UCP1)-mediated thermogenesis, a process suppressed in obesity. Phosphodiesterase 4 (PDE4) inhibition reduces inflammation by decreasing TNF-α release, and it has been linked to protection against metabolic dysfunction. Here, we investigated the effects of rolipram, a selective PDE4 inhibitor, in a model of diet-induced obesity. Male C57Bl/6 mice were fed a chow or high-fat diet (HFD; 60% fat) for 10 weeks and treated daily with rolipram (2 mg/kg, subcutaneous) or vehicle from week 8 on. Rolipram reduced body weight and adiposity in HFD-fed mice. It also enhanced BAT function, increasing thermogenic gene expression, UCP1 protein, noradrenaline content, and BAT temperature. PDE4 inhibition increased energy expenditure and heat production without altering locomotor activity. Corroborating these data, rolipram elevated cFOS expression and increased membrane excitability in neurons of the hypothalamic paraventricular nucleus, suggesting activation of hypothalamic pathways involved in energy balance and thermoregulation. These findings show that PDE4 inhibition attenuates diet-induced obesity by stimulating BAT thermogenesis and energy expenditure at least partially through central mechanisms, supporting PDE4 as a promising target for obesity treatment. ARTICLE HIGHLIGHTS: Metabolic alterations in obesity encompass impaired thermogenesis and sympathetic activity, underscoring the need for new metabolic targets to treat this disease. This study tested whether inhibition of PDE4 by rolipram enhances energy expenditure and brown adipose tissue activity. Rolipram reduced body weight and adiposity and increased brown adipose tissue temperature, UCP1 protein levels, noradrenaline levels, and enhanced excitability of hypothalamic paroventricular nucleus neurons. These findings suggest that central PDE4 inhibition promotes brown adipose tissue thermogenic activity and contributes to the metabolic effects of rolipram.

4 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
HVHellen Veida-Silva
Hellen Veida-Silva
LDLucas Kniess Debarba
Lucas Kniess Debarba
JAJosé Antunes-Rodrigues
José Antunes-Rodrigues
LELucila Leico K. Elias
Lucila Leico K. Elias
Repeated exposure to lipopolysaccharide (LPS) was shown to induce leptin resistance. This study aimed to assess hypothalamic neuroinflammation in animals challenged with repeated injections of LPS. Male C57Bl6 mice were assigned into three different groups according to the following treatments: 7 daily injections of saline (CT); 6 daily injections of saline + 1 injection of LPS on the last day (1LPS, 5ug/animal), or 7 daily injections of LPS (7LPS). After the single injection of LPS, there was a reduction in food intake and body weight. However, after the third injection, the 7LPS animals did not show the hypophagic effect, characterizing the desensitization to the endotoxin. To assess the responsiveness to leptin, control and LPS-treated groups received a leptin injection (5mg/kg, intraperitoneal) and food intake and the expression of p-STAT-3 in the hypothalamus were determined. Leptin injection reduced food intake and increased STAT3 phosphorylation in the control group, but not in the 7LPS group. Exogenous leptin did not present an additional effect on the 1LPS-induced hypophagia. We also observed that the expression of SOCS3, PTP1B, and TCPTP, leptin signaling counter-regulators, were increased in the 7LPS group compared to the control, but not in the 1LPS group. Furthermore, we observed neuroinflammation characterized by morphological microglial changes in both acute and repeated exposure to LPS, compared to the control group. These data indicate that repeated exposure to LPS leads to neuroinflammation, and expression of leptin counteracting proteins that ultimately contribute to leptin resistance in the hypothalamus.

31 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HVHellen Veida-Silva
Hellen Veida-Silva
LDLucas Kniess Debarba
Lucas Kniess Debarba
PZPatrik Saul Barbosa Zarpellon
Patrik Saul Barbosa Zarpellon
JAJose Antunes-Rodrigues
Jose Antunes-Rodrigues
LELucila L.K. Elias
Lucila L.K. Elias
Metabolic endotoxemia has been associated with obesity and insulin resistance; however, little is known about the mechanisms linking repeated inflammatory exposure to lipopolysaccharide (LPS) and long-term metabolic dysfunction. This study aimed to assess leptin responsiveness and to determine whether prior LPS exposure increases susceptibility to diet-induced weight gain. Male C57BL/6 mice received seven daily injections of saline (CT), a single LPS injection on the last day (1LPS), or seven daily LPS injections (7LPS). Acute LPS exposure induced hypophagia and body weight loss, whereas repeated exposure progressively attenuated these responses, indicating endotoxin tolerance. We next assessed leptin responsiveness and found that leptin failed to reduce food intake or increase hypothalamic STAT3 phosphorylation in 7LPS animals, consistent with leptin resistance. To investigate potential mechanisms underlying this impaired leptin response, we assessed negative regulators of leptin signaling. Repeated LPS exposure increased hypothalamic PTP1B and TCPTP expression and was associated with microglial morphological alterations. Despite these central changes, repeated LPS exposure did not produce detectable alterations in basal whole-body energy metabolism or body composition. However, animals previously exposed to repeated LPS showed increased food intake after a 12-h fast and greater body weight gain during subsequent high-fat diet feeding. Together, these findings indicate that repeated LPS exposure induces hypothalamic leptin resistance and microglial alterations while increasing susceptibility to diet-induced weight gain.